drug · small molecule
patient view →NILOTINIB
Marketedupdated 2mo agoby Xspray Pharma AB🔗 ChEMBL
Approvedcommunity read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for neoplasm and chronic myelogenous leukemia and 24 investigational indications.
targets
Tyrosine-protein kinase ABL1Bcr/Abl fusion protein
all catalysts(1)
approval · 1
News(0)
no news has mentioned this drug yet
comments(0)
5-min edit window · permanent after that